Form D · Pharmaceuticals
Merand Pharmaceuticals, Inc.
Charlottesville, VA · CIK 0001780981
Offering snapshot reported Jul 23, 2019 · SEC filing
- Reported sold
- $1.14M Offering amount: $1.25M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 12, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 23, 2019 | Initial | $1,135,000 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-344857
Series A Preferred Stock; upon conversion, issuance of underlying common shares
Source: Form D, filed Jul 23, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alan I. Annex | Director, Executive, Promoter |
| Brian H. Annex, M.D. | Director, Executive |
| Anthony Giordano | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1878 Catlin Road
Charlottesville, VA, 22901
Charlottesville, VA, 22901